Toward personalized treatment approaches for non-small-cell lung cancer
M Wang, RS Herbst, C Boshoff - Nature medicine, 2021 - nature.com
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
[HTML][HTML] The current state of the art and future trends in RAS-targeted cancer therapies
SR Punekar, V Velcheti, BG Neel… - Nature reviews Clinical …, 2022 - nature.com
Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
[HTML][HTML] Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
[HTML][HTML] Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
[PDF][PDF] Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …
[HTML][HTML] Advances in immunotherapy for hepatocellular carcinoma
B Sangro, P Sarobe, S Hervás-Stubbs… - Nature reviews …, 2021 - nature.com
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …
[HTML][HTML] Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Abstract PD-1 blockade unleashes CD8 T cells, including those specific for mutation-
associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit …
associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit …
[PDF][PDF] Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
Immunotherapy is a mainstay of non-small cell lung cancer (NSCLC) management. While
tumor mutational burden (TMB) correlates with response to immunotherapy, little is known …
tumor mutational burden (TMB) correlates with response to immunotherapy, little is known …
[PDF][PDF] The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …